Compare BioNano Genomics Inc (BNGO) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs IONQ Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while IONQ Inc trades at $44.98 (market cap $17.60B). The key difference: IONQ Inc is far larger — about 1288.4× BioNano Genomics Inc's market cap, and IONQ Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | IONQ | |
|---|---|---|
Market Cap | $13.66M | $17.60B |
Sector | Health | Technology |
52-Week High | $4.92 | $82.09 |
52-Week Low | $1.06 | $26.59 |
Enterprise Value | $16.26M | $15.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
IONQ trades at $45.20, up 6.28% today, with a bullish technical signal from moving averages and strong resistance near $46. The company reported Q2 2026 revenue growth of 287% to $80.1 million, though it missed EPS estimates. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism on quantum computing leadership.
Outlook is growth-driven but high-risk; revenue is projected to double in 2026, yet net losses exceed $1.4 billion. Key risks include profitability timeline, cash burn, and competitive pressures. Upside hinges on execution of its quantum roadmap and defense contracts, but volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
